FDA Approves OXYCONTIN — Knoa Pharma LLC

# FDA Approves OxyContin Generic Formulation for Knoa Pharma Knoa Pharma LLC received FDA approval for its generic oxycodone hydrochloride oral formulation, potentially opening significant market opportunities in the competitive opioid pain management sector and enabling the company to capture market share from brand-name OxyContin following patent expiration. The approval positions Knoa Pharma to benefit from increased generic penetration in the opioid market as insurers and healthcare providers shift toward lower-cost alternatives.